CHICAGO, July 3, 2018 /PRNewswire/ — SAI Global, a leading provider of integrated risk management solutions, and Environmental Resources Management (ERM), the global leader in environmental, health and safety (EHS) consultancy services, have today announced a strategic partnership to rapidly deploy best in class technology for the EHS market.

Through leading risk software, including a comprehensive EHS risk offering, together with ERM’s deep domain knowledge and software implementation best practice, the new partnership will provide technology, expertise, and will elevate innovative and best practice EHS solutions delivered to customers.

“Our clients trust us to help lead their EHS transformation, and our collaboration with ERM will contribute to our mission to develop real innovation with best practices,” said SAI Global CEO Peter Granat. “With this agreement in place our clients will benefit from real expertise, creating time to value and an ecosystem of innovation inclusive of market education, customer experience, and best practices to help them advance confidently and build better EHS outcomes.”

“We have been working with clients around the world for over 40 years, across a broad range of industry sectors, helping them to understand and manage their environmental, health and safety, risk, and social impacts,” commented Shawn Doherty, Global Head of Digital Business & Transformation at ERM. “Through the sharing of expertise and applying our deep industry experience working with our partners, we have helped many clients improve their EHS operations. We are delighted to add SAI Global to the ecosystem of trusted partners we have been collaborating with to better serve our clients on their digital EHS journey.”

“Collaboration and strategic partnerships in the EHS market have a key role to play when it comes to better serving customers by merging talent, expertise, and technology,” commented David Metcalfe, CEO of independent analyst firm, Verdantix. “Deepening ties between organizations like ERM and SAI Global fosters collaboration and innovation and allows them to offer services and solutions that help their customers effectively manage regulatory and financial risk, drive compliance, and boost efficiency.”

About SAI Global

SAI Global helps organizations proactively manage risk to create trust and achieve business excellence, growth, and sustainability. Our integrated risk management solutions are a combination of leading capabilities, services and advisory offerings that operate across the entire risk lifecycle allowing businesses to focus else ware. Together, these tools and knowledge enable clients to develop an integrated view of risk.

We have global reach with locations across Europe, the Middle East, Africa, the Americas, Asia and the Pacific. For more information visit www.saiglobal.com.

About ERM

ERM is the world’s leading environmental, health, safety, and sustainability company with over 4,500 consultants working across multiple industry sectors in more than 140 countries. The ERM Information Solutions specialty business practice is the most experienced EHS Information and Sustainability team in the market, as recognized year-over-year by outside analysts. We provide our clients with complete information solutions development life-cycle services ranging from strategy development and solution selection and design to implementation services and long-term sustainment support. For over 20 years ERM has helped clients meet their EHS information needs in all EHS and Sustainability business and functional areas. ERM provides clients value through a breadth of domain, business process and technical solution experience, coupled with objective and candid advice. This helps ensure that clients achieve safer, more sustainable operations while improving performance and reducing risk.

For more information visit www.erm.com.

Logo – https://photos.prnasia.com/prnh/20180215/2057977-1LOGO

SINGAPORE, July 5, 2018 /PRNewswire/ — Neovii pharmaceuticals AG of Rapperswil, Switzerland and Mundipharma have entered into an agreement giving Mundipharma the rights to develop and distribute its polyclonal antibody immunosuppressant Grafalon^®, in China and Japan from end October.

Grafalon^® is indicated in solid organ transplant for prevention and treatment of acute rejection, graft-vs-host disease (GvHD) in stem cell transplant (SCT) and in the treatment of aplastic anemia. Grafalon^® is the recognised standard of care in leading transplant centers.

Under its license, Mundipharma intends to strengthen the distribution and support of Grafalon^® in these key markets to advance the clinical development for the prevention of chronic GvHD in SCT.

Grafalon^® is currently approved for prevention of rejection and the treatment of acute steroid resistant rejection in solid organ transplant in China.

Grafalon^®, has been used for over 30 years to treat patients, and is currently available in over 50 countries worldwide. Neovii is a global leader in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology/oncology.

Juergen Pohle, Neovii CEO commented, “We are very enthusiastic to work with Mundipharma as a partner to develop Grafalon^® in China further by developing its indication for use in stem cell transplantation and further solidifying the position of Grafalon^® as a leading treatment for solid organ transplant patients in China.” 

Mundipharma CEO, Raman Singh, said, “We are excited to establish a partnership with Neovii that will have an positive impact on patients in China and Japan, who will have access to the leading technology for prevention of GvHD.

“We view Grafalon^® as a strategic complement to our existing haemotology and oncology franchise,” he added. “SCT continues to be the only curative therapy for many patients with leukemia, lymphoma, and Grafalon^® has the potential to help them avoid the debilitating and potentially fatal effects of GvHD.”

(R): GRAFALON is a registered trademark of Neovii.

About Grafalon^® 

Grafalon^® is a rabbit anti-human T-lymphocyte immunoglobulin (ATLG), used as part of immunosuppressive regimens for the prevention of graft versus host disease in stem cell transplantation, prevention and treatment of rejection in solid organ transplantation or as immunosuppressive in the treatment of aplastic anemia (in accordance with country-specific approved indications). With more than 200,000 treated patients to date in more than 50 countries, Grafalon^® enjoys worldwide recognition among solid organ and stem cell transplant teams and has transformed the way transplant teams manage the care of their patients around the world.

About Neovii

Neovii is an independent, dynamic, rapidly-growing and global biopharmaceutical company with a patient-focused mission to develop and market novel life-transforming therapies.

Neovii has been dedicated for over three decades to improving the outcomes in transplantation medicine and the treatment options for hemato-oncological as well as immune disorders. Neovii Pharmaceuticals AG’s global headquarters is located in Rapperswil, Switzerland and has a branch office in Massachusetts, USA. Its biotechnology manufacturing facility is in Graefelfing, Germany. Neovii’s products are available in over 50 countries worldwide.

About Mundipharma

Mundipharma is a network of independent associated companies which are privately owned entities covering pharmaceutical markets in Asia-Pacific, Latin America, the Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma is a prime example of an organization that consistently delivers high-quality medicines while standing by the values it represents. Its mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.

For more information please visit: www.neovii.com and www.mundipharma.com.sg

Logo – http://photos.prnasia.com/prnh/20150302/8521501264LOGO

BOSTON, July 6, 2018 /PRNewswire/ — Orion Health Group Limited (NZX:OHE/ASX:OHE) announced that it has reached an agreement in relation to Orion Health’s Rhapsody and Population Health businesses with Hg, a specialist technology investor committed to helping build global businesses with funds of c.GBP10 billion under management.

The agreement is for entities managed by Hg to acquire majority ownership of Orion Health’s Rhapsody business and to invest in Orion Health’s Population Health business.

Healthcare technology is a core investment area for Hg, having recently completed a number of transactions across the sector. This investment will be made from Hg’s Mercury 2 Fund.

Orion Health built the first Rhapsody integration engine in the late-1990s quickly becoming one of the most recognized interoperability platforms for healthcare organizations today. The combination of Rhapsody’s global team and Hg’s resources will extend Rhapsody as a leader in the interoperability platform space, building on both Rhapsody’s world class technology and highly rated customer service.

Philippe Houssiau, an experienced global technology executive, will step in to lead the Rhapsody business. Philippe has broad experience in leading healthcare businesses, consulting and start-ups, and is formerly CEO of Agfa Healthcare, CEO of Alliance Medical and a Senior Partner with PwC.

“This investment provides Orion Health with a tremendous opportunity to deliver on our vision for customers, our people and for the healthcare sector,” said Ian McCrae, Founder and CEO, Orion Health. “The Board and I believe that Hg is the right partner to accelerate the expansion of Rhapsody and support our vision for our Population Health business.”

“Hg has been researching the theme of interoperability and population health management in healthcare IT over many years,” said David Issott, Partner, Hg. “We believe this is a key global growth theme backed by substantial market funding and resources. Rhapsody provides fantastic products and services for this market and we look forward to partnering with the team at Rhapsody to maximize its potential across the globe. We are also excited to work with Ian and the team to realize the full potential of the Population Health business.”

“Rhapsody is a high-quality business with strong underlying fundamentals and a solid pipeline of new business,” said Philippe Houssiau, CEO Rhapsody. “We believe that the current healthcare market dynamic, with increasing requirement for ‘data liquidity’, presents Rhapsody with a real opportunity for further growth and a solid base for sustained performance. With a focused leadership team and the investment provided by Hg, Rhapsody will be able to leverage its core markets whilst expanding into selected and emerging segments.”

Full details of the transaction can be found in a Market Release on the investor page of Orion Health’s website here. Summary:

• Hg will acquire Rhapsody for NZ$205 million funded by debt and equity arranged by Hg. Orion Health will then utilize circa NZ$28 million of the transaction proceeds to acquire an ongoing 24.9% shareholding in the Rhapsody business.
• Hg will also acquire a 24.9% stake in Population Health by investing circa NZ$20 million in that business. Orion Health will invest around NZ$12 million of the Rhapsody transaction proceeds in Population Health based on an agreed enterprise value of NZ$50 million (on a cash free and debt free basis) together with NZ$30 million of net cash to fund ongoing operations.
• Orion Health will continue to own 100% of its Hospitals business.
• Following completion of the transaction, Orion Health will undertake a share buyback offer at an estimated price range of NZ$1.24-NZ$1.29 per share, with the final offer price dependent on Orion Health’s available cash immediately following completion taking into account transaction costs and working capital adjustments in relation to the Rhapsody transaction. Shareholders will have the option to accept the share buyback offer in respect of all or a specified proportion of their Orion Health shares.
• The bottom of the estimated buy back price range represents a premium of 46% to the closing price per Orion Health share of NZ$0.85 on July 2, 2018 and 55% to the volume weighted average trading price over the 20 trading days prior to July 3, 2018.

The injection of capital will provide investment for Orion Health to build leading global technology for the healthcare sector.

“As the healthcare sector evolves, so too has Orion Health. We believe the biggest advances in healthcare technology will come from a range of capabilities including advanced analytics and better data flow to address critical issues within the sector. In the face of growing and aging populations and the rise of chronic diseases, health systems the world over are under enormous strain. Our Population Health and Hospitals solutions are focused on helping healthcare organizations turn data into insights and clinical action and allow them to use this knowledge to optimize budgets and provide targeted patient care.

“This injection of capital will advance Orion Health’s businesses to reach their full potential over time. For our Population Health business, it will help strengthen our position as a market leader, and for our Hospitals business, it will further support its growth,” said McCrae. 

The transaction is subject to a number of conditions, including regulatory approval of the transaction and the share buyback offer by Orion Health’s shareholders. A notice of meeting describing the transaction and the share buyback offer will be circulated to shareholders. The independent directors have also commissioned an independent report from KordaMentha.

“This transaction is an important stepping stone in Orion Health’s efforts to build a solid and competitive business and provides our shareholders with choice in relation to their investment,” said Andrew Ferrier, Chairman of the Board, Orion Health. “We believe that providing shareholders both the option to cash-out at a substantial premium to the current trading price and the opportunity to elect to maintain an ongoing investment in Orion Health, including its 24.9% stake in Rhapsody and 75.1% stake in Population Health, is in the best interests of shareholders. This transaction has strong support from Orion Health’s Board and major shareholders.”

Enquiries:

Orion Health
Alex Mercer
P +1 857 488 4740
E alexme@orionhealth.com

Hg
Tom Eckersley
P +44 (0)20 7089 7888
E tom.eckersley@hgcapital.com

About Orion Health
Orion Health (NZX:OHE/ASX:OHE) is a health technology company that provides solutions which enable healthcare to over 110 million patients globally. Its open technology platform, Orion Health Amadeus, seamlessly integrates all forms of relevant data to enable population and personalized healthcare around the world. The company is committed to continual innovation to cement its position at the forefront of precision medicine. For more information visit www.orionhealth.com.

About Hg

Hg is a sector expert investor, committed to helping build ambitious businesses across the technology, services and industrial technology space, primarily in Europe. Deeply resourced sector teams focus on specific sub-sectors and investment themes to identify companies occupying an established position within a niche, and which have the potential to grow faster than their market, create employment and become the leader in their industry. Hg’s dedicated operations innovation team provides practical support to management teams to help them realise their growth ambitions. Based in London and Munich, Hg has funds under management of c. GBP10 billion serving some of the world’s leading institutional and private investors. For further details, please see www.hgcapital.com.

View original content:http://www.prnewswire.com/news-releases/hg-invests-in-orion-health-rhapsody-and-population-health-businesses-300676890.html

UPPSALA, Sweden, July 6, 2018 /PRNewswire/ — A new benchtop instrument from Thermo Fisher Scientific, the Phadia 200, enables new levels of flexibility and automation for laboratory testing facilities to aid in the diagnosis of allergy and autoimmunity conditions. The Phadia 200 is CE-marked, and the first installations are underway at select European sites.

The Phadia 200 benchtop instrument from Thermo Fisher Scientific enables new levels of flexibility and automation for laboratory testing facilities to aid in the diagnosis of allergy and autoimmunity conditions.

As the newest addition to the Phadia Laboratory Systems, the small, highly flexible Phadia 200 instrument can perform up to 700 different ImmunoCAP and EliA tests to aid in the diagnosis of allergic and autoimmune diseases. The instrument accommodates many types of workflows and provides facilities with the ability to create test menus for clinicians to meet their particular needs.

The Phadia 200 instrument is fully automated to reduce hands-on time and provide full traceability of all reagents. Its compact design enables smaller diagnostics facilities with expanding demands to increase their throughput and efficiency. It also minimizes the need to send samples offsite for testing, allowing labs to retain control of their own samples and improve their operational efficiencies. Like all Phadia instruments, the Phadia 200 instrument detects and quantifies clinically relevant antibodies in the blood to support clinical diagnosis in autoimmune and allergic disease.

The Phadia 200 also offers significant flexibility for large testing laboratories. It can process 42 samples at a time and provide up to 200 test results per day. For users of existing Phadia instruments, the Phadia 200 can be clustered with other Phadia instruments to enable flexible expansion. And, as testing needs grow, the unique Phadia Prime software allows integration into one network using a single software.

“Testing in the allergy and autoimmunity disease areas is changing faster than ever before in a consolidating laboratory market,” said Stefan Wolf, president, Immunodiagnostics, Thermo Fisher Scientific. “The Phadia 200 instrument is a significant step forward in bringing full automation and efficiency to diagnostic testing facilities of all sizes. It enables labs to offer a wide range of tests in fast-growing markets and supports continued growth in more established markets.”

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

Media Contact Information:
Martin Danielson
Lifecycle Director Systems
Immunodiagnostics
+46  731537908
martin.danielson@thermofisher.com

Photo – https://mma.prnewswire.com/media/715199/Thermo_Fisher_Phadia_200.jpg

STOCKHOLM, July 7, 2018 /PRNewswire/ — FOREO has announced the appointment of Filip Sedic as Chief Executive Officer to lead the company through its next phase of innovation and spur exponential growth. He assumes responsibilities immediately and will succeed Paul Peros who has stepped down to pursue new projects in the technology sector.

Filip Sedic currently holds the position of Chairman of the Board and is the primary inventor of FOREO’s award-winning product line including the LUNA cleansing devices and UFO smart mask treatment. As the original inspiration behind the brand and its strategic vision, Sedic will ensure a smooth transition, supporting further success.

“We would like to thank Paul Peros for the contribution he has made to the growth of FOREO from its beginning until to now,” Filip Sedic commented. “Through our five year journey, the company has developed into a strong organization, and is now ready to face up to an exciting new chapter in its history.” 

Swedish Beauty-Tech brand FOREO is stocked in more than 10,000 stores globally and since its founding in 2013, has won more than 90 international awards. 2017 saw a year of record growth with more the 10 million products delivered across 70 international markets.

For further media information please contact pr@foreo.com

About FOREO

Sweden-based FOREO aims to empower you to brighten your life, offering a new standard of beauty and wellbeing solutions to a wider audience than ever before. Our approach is a bold one: we don’t just improve existing designs; we tear them down completely and restart from the ground up – ensuring the best solutions are not reserved for the wealthy few. That’s also why we’re called FOREO, short for “For Every One.” We create groundbreaking, accessible solutions that bring happiness and benefit to everyday lives, at a fraction of the cost of professional treatments. We’re here to promote self-confidence: when you feel good, you look good – and our mission is complete.

Logo – https://mma.prnewswire.com/media/715597/FOREO_Logo.jpg

Source: Adlai Nortye Biopharma Co., Ltd.

HSINCHU and WUHAN, July 6, 2018 /PRNewswire/ — JHL Biotech announced today that the Center for Drug Evaluation (CDE), State Drug Administration of China (SDA) has approved JHL’s Phase I and Phase III Clinical Trial Application for a proposed rituximab biosimilar, JHL1101, to treat non-Hodgkin lymphoma. JHL will begin clinical trials of JHL1101 in the following months.

Racho Jordanov, JHL Biotech’s Co-Chairman and CEO stated, “This study adds to the data collected in the JHL1101 EU study and will differentiate JHL from many of its competitors. JHL Biotech is one of the few companies conducting clinical trials with biosimilars globally.”

About JHL Biotech

JHL Biotech Inc. is a biopharmaceutical company founded by a group of industry veterans with deep experience in biologics development and operations. With a mission to provide the world with affordable medicines of exceptional quality, the company is focused on research and development of new protein-based therapies and biosimilars. JHL Biotech’s experienced leadership team, ongoing global clinical trials for its pipeline of biosimilar candidates and two Asia-based world-class biologics manufacturing facilities built in accordance with United States, European Union, and ICH cGMP regulations and standards uniquely position the company to be a leading global supplier of high quality biologics. JHL Biotech is backed by premier financial firms, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity and the China Development Industrial Bank. For more information, please visit www.jhlbiotech.com.

Media Contact:
Ellis Chu: echu@jhlbiotech.com phone: +886 3-658-3899
Jill Liu: jliu@jhlbiotech.com phone: +886 3-658-3899
Amber Chen: achen@jhlbiotech.com phone: +886 3-658-3899

Logo – https://mma.prnewswire.com/media/333015/jhl_Logo.jpg

Source: Shanghai United Imaging Healthcare Co., Ltd.